{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T03:25:49Z","timestamp":1770521149728,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jgaronline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jgar.2014.02.006","type":"journal-article","created":{"date-parts":[[2014,3,19]],"date-time":"2014-03-19T00:17:44Z","timestamp":1395188264000},"page":"183-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011)"],"prefix":"10.1016","volume":"2","author":[{"given":"Robert K.","family":"Flamm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2014.02.006_bib0005","unstructured":"European Medicines Agency. Assessment report for Zinforo (ceftaroline fosamil) Procedure No. EMEA\/H\/C\/002252. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002252\/WC500132587.pdf [accessed 29.08.13]."},{"key":"10.1016\/j.jgar.2014.02.006_bib0010","unstructured":"Forest Laboratories, Inc. Teflaro\u00ae package insert. Forest Laboratories, Inc.; 2012. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/200327s009lbl.pdf [accessed 29.08.13]."},{"issue":"Suppl. 4","key":"10.1016\/j.jgar.2014.02.006_bib0015","first-page":"iv9","article-title":"Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity","volume":"65","author":"Biek","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 3","key":"10.1016\/j.jgar.2014.02.006_bib0020","first-page":"iii45","article-title":"Review of ceftaroline fosamil microbiology: integrated FOCUS studies","volume":"66","author":"Critchley","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2014.02.006_bib0025","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/jac\/dkp503","article-title":"Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae","volume":"65","author":"Moisan","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2014.02.006_bib0030","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1128\/AAC.00019-10","article-title":"Affinity of ceftaroline and other \u03b2-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae","volume":"54","author":"Kosowska-Shick","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 3","key":"10.1016\/j.jgar.2014.02.006_bib0035","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1093\/cid\/cis559","article-title":"Summary of ceftaroline fosamil clinical trial studies and clinical safety","volume":"55","author":"File","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.jgar.2014.02.006_bib0040","first-page":"iii53","article-title":"Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia","volume":"66","author":"Rank","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2014.02.006_bib0045","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/655827","article-title":"Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection","volume":"51","author":"Corey","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.jgar.2014.02.006_bib0050","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/cid\/cis563","article-title":"In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE surveillance program (2008\u20132010)","volume":"55","author":"Farrell","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2014.02.006_bib0055","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijantimicag.2012.12.013","article-title":"Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010)","volume":"41","author":"Farrell","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2014.02.006_bib0060","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/AAC.00330-12","article-title":"Summary of ceftaroline activity against pathogens in the United States 2010. Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program","volume":"56","author":"Flamm","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 3","key":"10.1016\/j.jgar.2014.02.006_bib0065","first-page":"iii69","article-title":"Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study","volume":"66","author":"Jones","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 4","key":"10.1016\/j.jgar.2014.02.006_bib0070","first-page":"iv17","article-title":"Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study","volume":"65","author":"Jones","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2014.02.006_bib0075","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1128\/AAC.01787-10","article-title":"In vitro activity of ceftaroline against Gram-positive and Gram-negative pathogens isolated from patients attending Canadian hospitals in 2009","volume":"55","author":"Karlowsky","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 3","key":"10.1016\/j.jgar.2014.02.006_bib0080","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1093\/cid\/cis561","article-title":"AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States","volume":"55","author":"Pfaller","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.jgar.2014.02.006_bib0085","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1093\/cid\/cis560","article-title":"Activity analyses of staphylococcal isolates from pediatric, adult and elderly patients: AWARE Ceftaroline Surveillance Program","volume":"55","author":"Sader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2014.02.006_bib0090","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Document M07-A9","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"10.1016\/j.jgar.2014.02.006_bib0095","series-title":"Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement. Document M100-S23","author":"Clinical and Laboratory Standards Institute","year":"2013"},{"key":"10.1016\/j.jgar.2014.02.006_bib0100","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, January 2013. http:\/\/www.eucast.org\/clinical_breakpoints\/ [accessed 02.01.13]."},{"key":"10.1016\/j.jgar.2014.02.006_bib0105","series-title":"Tygacil\u00ae package insert","author":"Wyeth Pharmaceuticals Inc.","year":"2011"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716514000289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716514000289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T20:50:02Z","timestamp":1538772602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716514000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S2213716514000289"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2014.02.006","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011)","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2014.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}